Cornileus Pharmaceuticals

Pharmaceutical research, manufacturing, and marketing of pellets and spheres in India with global operations.

About Cornileus Pharmaceuticals

Cornileus Pharmaceuticals is a Healthcare company. Pharmaceutical research, manufacturing, and marketing of pellets and spheres in India with global operations. The company has 14 employees. Its Indian entity Cornileus Pharmaceuticals Private Limited reported revenue of β‚Ή32.17 Cr. Cornileus Pharmaceuticals offers products and services including Pellets and Sugar or MCC Spheres. Its focus areas include Pharmaceuticals, Manufacturing, Pellets Production and Research and Development.

Company details

Cornileus Pharmaceuticals is engaged in research and development, manufacturing, and marketing of pharmaceutical pellets and related formulations, with facilities located in Visakhapatnam that adhere to cGMP guidelines. Global operations are extended across countries like Mexico, Brazil, and China to deliver healthcare solutions. Quality control measures are implemented to ensure compliance, while continuous product development is pursued to meet market demands. The companys efforts are focused on serving clients through professional approaches in the pharmaceutical sector.

Key Metrics
  • Indian entity revenue
    ₹32.17 Cr

    FY 2026 · +76% YoY

  • Indian entity net profit
    ₹70.4 Lakh

    FY 2026 · 2% margin

  • Indian entity EBITDA
    ₹4.52 Cr

    FY 2026 · 14% margin

  • Employee Count
    14

Products & Services of Cornileus Pharmaceuticals

Cornileus Pharmaceuticals offers a comprehensive portfolio of products and services, including Pellets and Sugar or MCC Spheres.

Pellets
Pharmaceutical Products

Research, manufacturing, and marketing of pharmaceutical pellets are carried out by the company for healthcare solutions.

Sugar or MCC Spheres
Pharmaceutical Products

Production and distribution of sugar or MCC spheres are managed by the company as part of its formulation offerings.

Board of directors of Cornileus Pharmaceuticals Private Limited (Cornileus Pharmaceuticals)

Cornileus Pharmaceuticals Private Limited is the primary company behind Cornileus Pharmaceuticals. The board of Cornileus Pharmaceuticals Private Limited currently have 4 directors; the longest-serving is Vijayalakshmi Nalamothu, appointed in 2017. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Vijayalakshmi Nalamothu
DIN 07964895
Director17 Oct 20179 yrs 1 moCornileus Pharmaceuticals Private Limited
Kiran Kumar Nalamothu
DIN 00669908
Managing Director05 Nov 20188 yrsCornileus Pharmaceuticals Private Limited
Jagarlamudi Suresh Babu
DIN 00141050
Director28 Dec 20205 yrs 10 moCornileus Pharmaceuticals Private Limited
Venkat Samraj Jagarlamudi
DIN 07689224
Director28 Dec 20205 yrs 10 moCornileus Pharmaceuticals Private Limited

Financials of Cornileus Pharmaceuticals

Figures of Cornileus Pharmaceuticals Private Limited, the primary company behind Cornileus Pharmaceuticals, for FY 2026. Revenue was ₹32.17 Cr (+76% year on year). Net profit was ₹70.4 Lakh (2% margin). EBITDA was ₹4.52 Cr (14% margin). Revenue has grown at a compounded annual rate of -7% over three years and +21% over five years.

  • ₹32.17 CrRevenue · FY 2026 · +76% YoY
  • ₹70.4 LakhNet profit · 2% margin
  • ₹4.52 CrEBITDA · 14% margin
  • ₹4.58 CrPaid-up capital
  • 124Employees (provident fund records)
  • -7%Revenue CAGR, 3 years
  • +21%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Cornileus Pharmaceuticals Private Limited are on its company page.

Premium access

Detailed financial statements for Cornileus Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Cornileus Pharmaceuticals

Cornileus Pharmaceuticals has 14 employees.

The primary company behind Cornileus Pharmaceuticals, Cornileus Pharmaceuticals Private Limited, reported revenue of β‚Ή32.17 Cr for FY 2026, up 76% year on year.

Cornileus Pharmaceuticals is engaged in research and development, manufacturing, and marketing of pharmaceutical pellets and related formulations, with facilities located in Visakhapatnam that adhere to cGMP guidelines. Global operations are extended across countries like Mexico, Brazil, and China to deliver healthcare solutions. Quality control measures are implemented to ensure compliance, while continuous product development is pursued to meet market demands. The companys efforts are focused on serving clients through professional approaches in the pharmaceutical sector.

Cornileus Pharmaceuticals offers Pellets and Sugar or MCC Spheres.

Cornileus Pharmaceuticals operates through Cornileus Pharmaceuticals Private Limited.

The legal entities of Cornileus Pharmaceuticals currently have 4 directors, including Jagarlamudi Suresh Babu, Kiran Kumar Nalamothu, Venkat Samraj Jagarlamudi and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available